Docket No. 17095CIPCON(AP) Garst, M.

$$HN$$
 R_2
 R_3
 R_4
 Y
 R_1
 R_1

formula (I)

wherein each Y is independently selected from the group consisting of N, N-CH3, O, S and C-R₁; R₁ is hydrogen, lower alkyl or oxo; R₂, R₃ and R₄ are independently selected from the group consisting of hydrogen, halogen, lower alkyl and lower alkenyl; n is an integer from 1 to 3; and a broken line beside a solid line indicates a single or double bond, provided that two double bonds are not on the same carbon in the case when n=1, and their pharmaceutically acceptable salts and esters as appropriate, wherein said composition lowers intraocular pressure and provides neuroprotection.

14) (Amended) An article of manufacture comprising packaging material and a pharmaceutical combination comprising at least one alpha adrenergic agent and at least one prostaglandin and their pharmaceutically acceptable salts and esters as appropriate, wherein the pharmaceutical agents are effective in controlling elevated intraocular pressure associated with glaucoma and ocular hypertension and providing neuroprotection, and wherein the packaging material comprises a label which indicates that said combination can be used for control of elevated intraocular pressure or in treating glaucoma, and wherein said alpha adrenergic agent is represented by formula (I)

formula (I)

wherein each Y is independently selected from the group consisting of N, N-CH3, O, S and C-R1; R1 is hydrogen, lower alkyl or oxo; R2, R3 and R4 are independently selected from the group